Oncotarget
Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.
Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases.The term was introduced in the inaugural Editorial,Introducing Oncotarget.
As of January 1, 2022,Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.
Publication Alerts
SSP 47th Annual Meeting
Post-Publication Promotion
Learn about ourFREE
Impact Journals, LLC is the publisher of Oncotarget:www.impactjournals.com.
Impact Journals is a member of theWellcome Trust List of Compliant Publishers.
Impact Journals is a member of theSociety for Scholarly Publishing.
On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control.This malicious action will be reported to the FBI.
Current Volume
This Month's Popular DOIs
(Crossref resolutions)
| 10.18632/ONCOTARGET.23208 |
| 10.18632/ONCOTARGET.6429 |
| 10.18632/ONCOTARGET.9859 |
| 10.18632/ONCOTARGET.13553 |
| 10.18632/ONCOTARGET.14401 |
| 10.18632/ONCOTARGET.15422 |
| 10.18632/ONCOTARGET.16407 |
| 10.18632/ONCOTARGET.19087 |
Most popular Oncotarget DOIs, measured by the number of times each DOI was successfully resolved.
Most Popular DOIs Published in 2024
(Crossref Data)
Top-10 Most Popular DOIs of 2024
(Crossref Data)
Milestones in Modern Scholarly Publishing
On August 25, 2022, the Office of Science and Technology Policy announced a new government policy legislating the immediate public release of all United States-funded research publications by 2025.Learn more here andhere.
On May 23, 2023, the Council of the European Union adopted conclusions on high-quality, transparent, open, trustworthy, and equitable scholarly publishing. The Council calls for immediate and unrestricted open access to publishing research involving public funds.Learn more.
Oncotarget.org: Blog Posts on
New & Trending Papers
Oncotarget.net: Latest Insights
From Our Authors
July 10, 2018
About The Cover
The cover for issue 53 of Oncotarget features Figure 4, "Image depicting primary (left) and metastatic lung (right) osteosarcoma as visualized by indocyanine green dye angiography," byCrasto, et al.
Table of Contents
Research Papers
| Heterogeneous expression of Lgr5 as a risk factor for focal invasion and distant metastasis of colorectal carcinoma |
https://doi.org/10.18632/oncotarget.23144 Zhong Zheng,Huiping Yu,Qin Huang,Hongyan Wu,Yao Fu,Jiong Shi,Ting Wang, and Xiangshan Fan |
| 30025-30033 |
| Abstract | PDF | HTML | How to cite |
| The matrix protein Fibulin-3 promotes KISS1R induced triple negative breast cancer cell invasion |
https://doi.org/10.18632/oncotarget.25682 Michelle M. Noonan,Magdalena Dragan,Michael M. Mehta,David A. Hess,Muriel Brackstone,Alan B. Tuck,Navin Viswakarma,Ajay Rana,Andy V. Babwah,Frederic E. Wondisford, and Moshmi Bhattacharya |
| 30034-30052 |
| Abstract | PDF | HTML | Supplementary Information | How to cite |
| miR-363 confers taxane resistance in ovarian cancer by targeting the Hippo pathway member, LATS2 |
https://doi.org/10.18632/oncotarget.25698 Zeinab Mohamed,Mohamed Kamel Hassan,Safwat Okasha,Takashi Mitamura,Sarah Keshk,Yusuke Konno,Tatsuya Kato,Sherif F. EL-khamisy,Yusuke Ohba, and Hidemichi Watari |
| 30053-30065 |
| Abstract | PDF | HTML | Supplementary Information | How to cite |
| Combined inhibition of PI3K and Src kinases demonstrates synergistic therapeutic efficacy in clear-cell renal carcinoma |
https://doi.org/10.18632/oncotarget.25700 Caroline Roelants,Sofia Giacosa,Catherine Pillet,Rémi Bussat,Pierre Champelovier,Olivier Bastien,Laurent Guyon,Valentin Arnoux,Claude Cochet, and Odile Filhol |
| 30066-30078 |
| Abstract | PDF | HTML | Supplementary Information | How to cite |
| Prokineticin 2 expression as a novel prognostic biomarker for human colorectal cancer |
https://doi.org/10.18632/oncotarget.25706 Yu Yoshida,Takanori Goi,Hidetaka Kurebayashi,Mitsuhiro Morikawa,Yasuo Hirono, and Kanji Katayama |
| 30079-30091 |
| Abstract | PDF | HTML | How to cite |
| Characterization of TRKA signaling in acute myeloid leukemia |
https://doi.org/10.18632/oncotarget.25723 Shelley M. Herbrich,Sankaranarayanan Kannan,Riitta M. Nolo,Marisa Hornbaker,Joya Chandra, and Patrick A. Zweidler-McKay |
| 30092-30105 |
| Abstract | PDF | HTML | Supplementary Information | How to cite |
| Diagnostic tools in the differential diagnosis of giant cell-rich lesions of bone at biopsy |
https://doi.org/10.18632/oncotarget.25725 Jan Rehkämper,Konrad Steinestel,Birte Jeiler,Sandra Elges,Elena Hekeler,Sebastian Huss,Jan Sperveslage,Jendrik Hardes,Arne Streitbürger,Georg Gosheger,Eva Wardelmann,Daniel Baumhoer,Marcel Trautmann, and Wolfgang Hartmann |
| 30106-30114 |
| Abstract | PDF | HTML | How to cite |
| Epigenetic activation of HORMAD1 in basal-like breast cancer: role in Rucaparib sensitivity |
https://doi.org/10.18632/oncotarget.25728 Xian Wang,Ying Tan,Xixi Cao,Jin Ah Kim,Tianmeng Chen,Yiheng Hu,Matthew Wexler, and Xiaosong Wang |
| 30115-30127 |
| Abstract | PDF | HTML | Supplementary Information | How to cite |
| Clonal heterogeneity ofFLT3-ITD detected by high-throughput amplicon sequencing correlates with adverse prognosis in acute myeloid leukemia |
https://doi.org/10.18632/oncotarget.25729 Katrin Schranz,Max Hubmann,Egor Harin,Sebastian Vosberg,Tobias Herold,Klaus H. Metzeler,Maja Rothenberg-Thurley,Hanna Janke,Kathrin Bräundl,Bianka Ksienzyk,Aarif M.N. Batcha,Sebastian Schaaf,Stephanie Schneider,Stefan K. Bohlander,Dennis Görlich,Wolfgang E. Berdel,Bernhard J. Wörmann,Jan Braess,Stefan Krebs,Wolfgang Hiddemann,Ulrich Mansmann,Karsten Spiekermann, and Philipp A. Greif |
| 30128-30145 |
| Abstract | PDF | HTML | Supplementary Information | How to cite |
| Identification of integrin drug targets for 17 solid tumor types |
https://doi.org/10.18632/oncotarget.25731 Adith S. Arun,Clifford G. Tepper, and Kit S. Lam |
| 30146-30162 |
| Abstract | PDF | HTML | Supplementary Information | How to cite |
| Disulfiram reduces metastatic osteosarcoma tumor burden in an immunocompetentBalb/c or-thotopic mouse model |
https://doi.org/10.18632/oncotarget.25733 Jared Anthony Crasto,Mitchell Stephen Fourman,Alejandro Morales-Restrepo,Adel Mahjoub,Jonathan Brendan Mandell,Kavita Ramnath,Jessica C. Tebbets,Rebecca J. Watters, and Kurt Richard Weiss |
| 30163-30172 |
| Abstract | PDF | HTML | Supplementary Information | How to cite | Press Release |
| Tumor endothelial marker 8 promotes cancer progression and metastasis |
https://doi.org/10.18632/oncotarget.25734 Anette M. Høye,Sofie D. Tolstrup,Edward R. Horton,Monica Nicolau,Helen Frost,Jung H. Woo,Jeremy P. Mauldin,Arthur E. Frankel,Thomas R. Cox, and Janine T. Erler |
| 30173-30188 |
| Abstract | PDF | HTML | Supplementary Information | How to cite |
Clinical Research Papers
| Comparing children and adults with medulloblastoma: a SEER based analysis |
https://doi.org/10.18632/oncotarget.23773 Qian Li,Zhenguo Dai,Yuze Cao, and Lihua Wang |
| 30189-30198 |
| Abstract | PDF | HTML | How to cite |
| The role of E-cadherin and β-catenin in laryngeal cancer |
https://doi.org/10.18632/oncotarget.25680 Carlos Eduardo Nardi,Rogério Aparecido Dedivitis,Ricardo Camillo de Almeida,Leandro Luongo de Matos, and Claudio Roberto Cernea |
| 30199-30209 |
| Abstract | PDF | HTML | How to cite |
Copyright © 2025 Rapamycin Press LLC dba Impact Journals